Evidence map›Paper›PMID 24392029›Full record

ArticlePloS one2013

Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling.

Sherif A Ibrahim, Hebatallah Hassan, Laura Vilardo, Sampath Katakam Kumar, Archana Vijaya Kumar, Reinhard Kelsch, Cornelia Schneider, Ludwig Kiesel, Hans Theodor Eich, Ileana Zucchi and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.

  1. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.Journal of experimental & clinical cancer research : CR · 2019
    Pooled it
  2. Review
  3. Article
  4. SDC1 is a critical transmembrane proteoglycan in breast cancer.World journal of surgical oncology · 2025
    Review
  5. Review
  6. Article
  7. The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Sherif A IbrahimDepartment of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany ; Department of Zoology, Faculty of Science, Cairo University, Giza, Egypt.
Hebatallah HassanDepartment of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany ; Department of Zoology, Faculty of Science, Cairo University, Giza, Egypt.
Laura VilardoITB-CNR, Segrate Milan, Italy.
Sampath Katakam KumarDepartment of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany.
Archana Vijaya KumarDepartment of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany.
Reinhard KelschInstitute of Transfusion Medicine and Transplantation Immunology, University Hospital Münster, Münster, Germany.
Cornelia SchneiderDepartment of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany.
Ludwig KieselDepartment of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany.
Hans Theodor EichDepartment of Radiotherapy - Radiooncology, University Hospital Münster, Münster, Germany.
Ileana ZucchiITB-CNR, Segrate Milan, Italy.
Rolland ReinboldITB-CNR, Segrate Milan, Italy.
Burkhard GreveDepartment of Radiotherapy - Radiooncology, University Hospital Münster, Münster, Germany.
Martin GötteDepartment of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany.
University Hospital Münster · DEInstitute of Biomedical Technologies · ITCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Syndecan-1 (CD138), a heparan sulfate proteoglycan, acts as a coreceptor for growth factors and chemokines and is a molecular marker associated with epithelial-mesenchymal transition during development and carcinogenesis. Resistance of Syndecan-1-deficient mice to experimentally-induced tumorigenesis has been linked to altered Wnt-responsive precursor cell pools, suggesting a potential role of Syndecan-1 in breast cancer cell stem function. However, the precise molecular mechanism is still elusive. Here, we decipher the functional impact of Syndecan-1 knockdown using RNA interference on the breast cancer stem cell phenotype of human triple-negative MDA-MB-231 and hormone receptor-positive MCF-7 cells in vitro employing an analytical flow cytometric approach. Successful Syndecan-1 siRNA knockdown was confirmed by flow cytometry. Side population measurement by Hoechst dye exclusion and Aldehyde dehydrogenase-1 activity revealed that Syndecan-1 knockdown in MDA-MB-231 cells significantly reduced putative cancer stem cell pools by 60% and 27%, respectively, compared to controls. In MCF-7 cells, Syndecan-1 depletion reduced the side population by 40% and Aldehyde dehydrogenase-1 by 50%, repectively. In MDA-MB-231 cells, the CD44(+)CD24(-/low) phenotype decreased significantly by 6% upon siRNA-mediated Syndecan-1 depletion. Intriguingly, IL-6, its receptor sIL-6R, and the chemokine CCL20, implicated in regulating stemness-associated pathways, were downregulated by >40% in Syndecan-1-silenced MDA-MB-231 cells, which showed a dysregulated response to IL-6-induced shifts in E-cadherin and vimentin expression. Furthermore, activation of STAT-3 and NFkB transcription factors and expression of a coreceptor for Wnt signaling, LRP-6, were reduced by >45% in Syndecan-1-depleted cells compared to controls. At the functional level, Syndecan-1 siRNA reduced the formation of spheres and cysts in MCF-7 cells grown in suspension culture. Our study demonstrates the viability of flow cytometric approaches in analyzing cancer stem cell function. As Syndecan-1 modulates the cancer stem cell phenotype via regulation of the Wnt and IL-6/STAT3 signaling pathways, it emerges as a promising novel target for therapeutic approaches.

Indexed as

Signal TransductionAldehyde Dehydrogenase 1 FamilyCell DifferentiationDown-RegulationGene Knockdown TechniquesGene SilencingHumansInterleukin-6IsoenzymesLow Density Lipoprotein Receptor-Related Protein-6MCF-7 CellsNeoplastic Stem CellsNF-kappa BRetinal DehydrogenaseRNA, Small InterferingSpheroids, CellularAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanALDH1A1 protein, mouseInterleukin-6IsoenzymesLow Density Lipoprotein Receptor-Related Protein-6LRP6 protein, humanNF-kappa BRetinal DehydrogenaseRNA, Small InterferingSTAT3 Transcription FactorSyndecan-1Wnt Proteins

Identifiers

PMID24392029
PMCPMC3877388
OpenAlexW2053832323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.